Skip to main content

Advertisement

SpringerLink
Log in

Use of proton pump inhibitors in dialysis patients: a double-edged sword?

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Large cohort-based studies have shown that proton pump inhibitors (PPIs) are linked to rare but multiple and varied secondary events when used in the general population. Although clinicians accept the negative effects of PPIs on renal function, there is a lack of available data regarding the potential consequences of their use by dialysis patients in whom the risk of gastrointestinal bleeding is quite high. This review aims to highlight the risks and benefits of PPIs use in dialysis patients. To summarize, the benefit on the reduction of high digestive bleeding seems certain, but without any beneficial impact on overall survival. The impact on quality of life seems to be significant. The data on the occurrence of peritonitis during PPIs treatment are very contradictory. There is evidence regarding the occurrence of hypomagnesaemia in haemodialysis patients with PPIs; which may lead to increase bone fragility. New data show an increased cardiovascular risk and even a risk of death linked to the use of PPIs on dialysis. Several mechanisms of IPP toxicity are advanced to explain these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray Spira R (2020) Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 76(3):449–457. https://doi.org/10.1007/s00228-019-02810-1

    Article  CAS  PubMed  Google Scholar 

  2. Poly TN, Islam MM, Yang HC, Wu CC, Li YC (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 30(1):103–114. https://doi.org/10.1007/s00198-018-4788-y

    Article  CAS  PubMed  Google Scholar 

  3. Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435–2442. https://doi.org/10.1001/jama.2013.280490

    Article  CAS  PubMed  Google Scholar 

  4. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O'Corragain OA, Korpaisarn S, Erickson SB (2015) Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 37(7):1237–1241. https://doi.org/10.3109/0886022X.2015.1057800

    Article  CAS  PubMed  Google Scholar 

  5. Casula M, Scotti L, Galimberti F, Mozzanica F, Tragni E, Corrao G, Catapano AL (2018) Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis 277:123–129. https://doi.org/10.1016/j.atherosclerosis.2018.08.035

    Article  CAS  PubMed  Google Scholar 

  6. Sehested TSG, Gerds TA, Fosbøl EL, Hansen PW, Charlot MG, Carlson N, Hlatky MA, Torp-Pedersen C, Gislason GH (2018) Long-term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med 283(3):268–281. https://doi.org/10.1111/joim.12698

    Article  CAS  PubMed  Google Scholar 

  7. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA (2015) Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 10(6):e0128004. https://doi.org/10.1371/journal.pone.0128004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L (2017) Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol 23(35):6500. https://doi.org/10.3748/wjg.v23.i35.6500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sierra F, Suarez M, Rey M, Vela MF (2007) Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26(4):545–553. https://doi.org/10.1111/j.1365-2036.2007.03407.x

    Article  CAS  PubMed  Google Scholar 

  10. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176(2):238–246. https://doi.org/10.1001/jamainternmed.2015.7193

    Article  PubMed  PubMed Central  Google Scholar 

  11. Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, Lohr JW (2016) Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 17(1):112. https://doi.org/10.1186/s12882-016-0325-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z (2016) Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 27(10):3153–3163. https://doi.org/10.1681/asn.2015121377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z (2017) Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int 91(6):1482–1494. https://doi.org/10.1016/j.kint.2016.12.021

    Article  CAS  Google Scholar 

  14. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, Investigators COMPASS (2019) Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 157(3):682–691.e2. https://doi.org/10.1053/j.gastro.2019.05.056

    Article  CAS  PubMed  Google Scholar 

  15. Simin J, Liu Q, Fornes R, Brusselaers N (2020) Safety of proton pump inhibitors questioned based on a large randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 158(4):1172–1173. https://doi.org/10.1053/j.gastro.2019.07.067

    Article  CAS  PubMed  Google Scholar 

  16. Liang C-C, Muo C-H, Wang IK, Chang CT, Chou CY, Liu JH, Yen TH, Huang CC, Chung CJ (2014) Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications. PLoS One 9(2):e87952. https://doi.org/10.1371/journal.pone.0087952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Liang C-C, Wang S-M, Kuo H-L, Chang CT, Liu JH, Lin HH, Wang IK, Yang YF, Lu YJ, Chou CY, Huang CC (2014) Upper gastrointestinal bleeding in patients with CKD. Clin J Am Soc Nephrol 9(8):1354–1359. https://doi.org/10.2215/CJN.09260913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Trivedi H, Yang J, Szabo A (2015) Gastrointestinal bleeding in patients on long-term dialysis. J Nephrol 28(2):235–243. https://doi.org/10.1007/s40620-014-0132-6

    Article  CAS  PubMed  Google Scholar 

  19. Yang J-Y, Lee T-C, Montez-Rath ME, Paik J, Chertow GM, Desai M, Winkelmayer WC (2012) Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 23(3):495–506. https://doi.org/10.1681/asn.2011070658

    Article  PubMed  PubMed Central  Google Scholar 

  20. Loperfido S, Baldo V, Piovesana E, Bellina L, Rossi K, Groppo M, Caroli A, Dal Bò N, Monica F, Fabris L, Heras Salvat H, Bassi N, Okolicsanyi L (2009) Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 70(2):212–224. https://doi.org/10.1016/j.gie.2008.10.051

    Article  PubMed  Google Scholar 

  21. Kuo C-C, Kuo H-W, Lee IM, Lee C-T, Yang C-Y (2013) The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol 14(1):15. https://doi.org/10.1186/1471-2369-14-15

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lin X-H, Lin C-C, Wang Y-J, Luo JC, Young SH, Chen PH, Hou MC, Lee FY (2018) Risk factors of the peptic ulcer bleeding in aging uremia patients under regular hemodialysis. J Chin Med Assoc 81(12):1027–1032. https://doi.org/10.1016/j.jcma.2018.03.007

    Article  PubMed  Google Scholar 

  23. Laeeq SM, Tasneem AA, Hanif FM, Luck NH, Mandhwani R, Wadhva R (2017) Upper gastrointestinal bleeding in patients with end stage renal disease: causes, characteristics and factors associated with need for endoscopic therapeutic intervention. J Transl Int Med 5(2):106–111. https://doi.org/10.1515/jtim-2017-0019

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chalasani N, Cotsonis G, Wilcox CM (1996) Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Am J Gastroenterol 91(11):2329–2332

    CAS  PubMed  Google Scholar 

  25. Zuckerman GR, Cornette GL, Clouse RE, Harter HR (1985) Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 102(5):588–592. https://doi.org/10.7326/0003-4819-102-5-588

    Article  CAS  PubMed  Google Scholar 

  26. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO (2003) Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64(4):1455–1461. https://doi.org/10.1046/j.1523-1755.2003.00225.x

    Article  PubMed  Google Scholar 

  27. Tani N, Harasawa S, Suzuki S, Miwa M, Sakita R, Nomiyama T, Watanabe H, Senoue I, Kikuchi K, Miwa T (1980) Lesions of the upper gastrointestinal tract in patients with chronic renal failure. Gastroenterol Jpn 15(5):480–484. https://doi.org/10.1007/BF02773912

    Article  CAS  PubMed  Google Scholar 

  28. Lee Y-C, Hung S-Y, Wang H-H, Wang H-K, Lin C-W, Chang M-Y, Ho L-C, Chen Y-T, Wu C-F, Chen H-C, Wang W-M, Sung J-M, Chiou Y-Y, Lin S-H (2015) Different risk of common gastrointestinal disease between groups undergoing hemodialysis or peritoneal dialysis or with non-end stage renal disease: a nationwide population-based cohort study. Medicine (Baltimore) 94(36):e1482. https://doi.org/10.1097/MD.0000000000001482

    Article  CAS  Google Scholar 

  29. Gladziwa U, Hasse G, Handt S, Riehl J, Wietholtz H, Dakshinamurty KV, Glöckner WM, Sieberth HG (1993) Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transplant 8(4):301–306. https://doi.org/10.1093/oxfordjournals.ndt.a092460

    Article  CAS  PubMed  Google Scholar 

  30. Jaspersen D, Fassbinder W, Heinkele P, Kronsbein H, Schorr W, Raschka C, Brennenstuhl M (1995) Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol 30(5):585–588. https://doi.org/10.1007/BF02367783

    Article  CAS  PubMed  Google Scholar 

  31. Gu M, Xiao S, Pan X, Zhang G (2013) Helicobacter pylori infection in dialysis patients: a meta-analysis. Gastroenterol Res Pract 2013:785892. https://doi.org/10.1155/2013/785892

    Article  PubMed  PubMed Central  Google Scholar 

  32. Sood P, Kumar G, Nanchal R, Sakhuja A, Ahmad S, Ali M, Kumar N, Ross EA (2012) Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol 35(3):216–224. https://doi.org/10.1159/000336107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yang J-Y, Lee T-C, Montez-Rath ME, Chertow GM, Winkelmayer WC (2013) Risk factors of short-term mortality after acute nonvariceal upper gastrointestinal bleeding in patients on dialysis: a population-based study. BMC Nephrol 14(1):97. https://doi.org/10.1186/1471-2369-14-97

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bailie GR, Mason NA, Elder SJ, Andreucci VE, Greenwood RN, Akiba T, Saito A, Bragg-Gresham JL, Gillespie BW, Young EW (2006) Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Hemodial Int 10(2):180–188. https://doi.org/10.1111/j.1542-4758.2006.00092.x

    Article  PubMed  Google Scholar 

  35. Fusaro M, D’Arrigo G, Pitino A, Iervasi G, Tentori F, Robinson B, Aghi A, Bieber B, Mccullogh K, Fabris F, Plebani M, Giannini S, Gallieni M, Tripepi G (2019) Increased risk of bone fractures in hemodialysis patients treated with proton pump inhibitors in real world: results from the dialysis outcomes and practice patterns study (DOPPS). J Bone Miner Res 34(12):2238–2245. https://doi.org/10.1002/jbmr.3842

    Article  CAS  PubMed  Google Scholar 

  36. Kosedo I, Tokushige A, Takumi T, Yoshikawa A, Teraguchi K, Takenouchi K, Shiraishi K, Ikeda D, Imamura M, Sonoda T, Kanda D, Ikeda Y, Ido A, Ohishi M (2020) Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry. Eur J Intern Med 72:79–87. https://doi.org/10.1016/j.ejim.2019.11.002

    Article  CAS  PubMed  Google Scholar 

  37. Vangala C, Niu J, Lenihan CR, Mitch WE, Navaneethan SD, Winkelmayer WC (2018) Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis. Clin J Am Soc Nephrol 13(10):1534–1541. https://doi.org/10.2215/cjn.02190218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, Pascual J, Aljama P, Optimizing Results in Dialysis (ORD) Group (2018) Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep 3(2):374–384. https://doi.org/10.1016/j.ekir.2017.11.001

    Article  PubMed  Google Scholar 

  39. Fusaro M, Noale M, Tripepi G, Giannini S, D'Angelo A, Pica A, Calò LA, Miozzo D, Gallieni M (2013) Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis. Drug Saf 36(8):635–642. https://doi.org/10.1007/s40264-013-0062-6

    Article  CAS  PubMed  Google Scholar 

  40. Maeda S, Yamaguchi M, Maeda K, Kobayashi N, Izumi N, Nagai M, Obayashi T, Ohashi W, Katsuno T, Nobata H, Ito Y (2019) Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. PLoS One 14(11):e0224859. https://doi.org/10.1371/journal.pone.0224859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pérez-Fontan M, Machado Lopes D, García Enríquez A, López-Calviño B, López-Muñiz A, García Falcón T, Rodríguez-Carmona A (2016) Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One 11(2):e0148806. https://doi.org/10.1371/journal.pone.0148806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Song YR, Kim HJ, Kim J-K, Kim SG, Kim SE (2015) Proton-pump inhibitors for prevention of upper gastrointestinal bleeding in patients undergoing dialysis. World J Gastroenterol 21(16):4919–4924. https://doi.org/10.3748/wjg.v21.i16.4919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Liang C-C, Wang IK, Lin H-H, Yeh H-C, Liu J-H, Kuo H-L, Hsu W-M, Huang C-C, Chang C-T (2011) Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients. Ren Fail 33(3):323–328. https://doi.org/10.3109/0886022X.2011.560407

    Article  CAS  PubMed  Google Scholar 

  44. Strid H, Simrén M, Johansson A, Svedlund J, Samuelsson O, Björnsson ES (2002) The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant 17(8):1434–1439. https://doi.org/10.1093/ndt/17.8.1434

    Article  PubMed  Google Scholar 

  45. Namikoshi T, Harada K, Hatta H, Tokura T, Oshiro Y, Nishizaki T, Obata T, Mori M, Fueki T, Fujimoto S, Haruna Y, Kuwabara A, Yorimitsu D, Ihoriya C, Kadoya H, Itano S, Fujimoto Y, Komai N, Sasaki T, Kashihara N (2016) Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis. Clin Exp Nephrol 20(1):134–142. https://doi.org/10.1007/s10157-015-1130-2

    Article  CAS  PubMed  Google Scholar 

  46. Zhong H-J, Lin D, Lu Z-Y, Yang W-Y, Chen Y (2019) Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: a meta-analysis. J Clin Pharm Ther 44(2):209–215. https://doi.org/10.1111/jcpt.12769

    Article  CAS  PubMed  Google Scholar 

  47. Abdel-Razik A, Abdelsalam M, Gad DF, Abdelwahab A, Tawfik M, Elzehery R, Elhelaly R, Hasan AS, El-Wakeel N, Eldars W (2019) Recurrence of spontaneous bacterial peritonitis in cirrhosis: novel predictors. Eur J Gastroenterol Hepatol 32(6):718–726. https://doi.org/10.1097/MEG.0000000000001578

    Article  CAS  Google Scholar 

  48. Desbuissons G, Deray G, Mercadal L (2018) Inhibiteurs de la pompe à protons et rein. Nephrol Ther 14:S115–S124. https://doi.org/10.1016/j.nephro.2017.06.005

    Article  PubMed  Google Scholar 

  49. Park CH, Kim EH, Roh YH, Kim HY, Lee SK (2014) The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One 9(11):e112558. https://doi.org/10.1371/journal.pone.0112558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ago R, Shindo T, Banshodani M, Shintaku S, Moriishi M, Masaki T, Kawanishi H (2016) Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: a cross-sectional, 1-year, retrospective cohort study. Hemodial Int 20(4):580–588. https://doi.org/10.1111/hdi.12437

    Article  PubMed  Google Scholar 

  51. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ (2014) Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol 39(3):204–209. https://doi.org/10.1159/000360011

    Article  CAS  PubMed  Google Scholar 

  52. Misra PS, Alam A, Lipman ML, Nessim SJ (2015) The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol 16(1):136. https://doi.org/10.1186/s12882-015-0139-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mikolasevic I, Milic S, Stimac D, Zaputovic L, Lukenda Zanko V, Gulin T, Jakopcic I, Klaric D, Gulin M, Orlic L (2016) Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis? Eur J Intern Med 30:99–103. https://doi.org/10.1016/j.ejim.2016.01.026

    Article  CAS  PubMed  Google Scholar 

  54. Nakashima A, Ohkido I, Yokoyama K, Mafune A, Urashima M, Yokoo T (2015) Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: a cross-sectional study. PLoS One 10(11):e0143656. https://doi.org/10.1371/journal.pone.0143656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sakaguchi Y, Hamano T, Wada A, Hoshino J, Masakane I (2018) Magnesium and risk of hip fracture among patients undergoing hemodialysis. J Am Soc Nephrol 29(3):991–999. https://doi.org/10.1681/ASN.2017080849

    Article  CAS  PubMed  Google Scholar 

  56. Belluci MM, Schoenmaker T, Rossa-Junior C, Orrico SR, de Vries TJ, Everts V (2013) Magnesium deficiency results in an increased formation of osteoclasts. J Nutr Biochem 24(8):1488–1498. https://doi.org/10.1016/j.jnutbio.2012.12.008

    Article  CAS  PubMed  Google Scholar 

  57. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26(6):1466–1475. https://doi.org/10.1681/asn.2014040414

    Article  CAS  PubMed  Google Scholar 

  58. Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280(20):5052–5064. https://doi.org/10.1111/febs.12478

    Article  CAS  PubMed  Google Scholar 

  59. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778–781. https://doi.org/10.1016/j.amjmed.2005.02.007

    Article  CAS  PubMed  Google Scholar 

  60. Kirkpantur A, Altun B, Arici M, Turgan C (2009) Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract 63(2):261–268. https://doi.org/10.1111/j.1742-1241.2008.01883.x

    Article  CAS  PubMed  Google Scholar 

  61. Li S, Liu F, Chen C, Zhu W, Ma J, Hu J, Xu J, Hong K (2019) Real-World relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel. Int Heart J 60(4):910–918. https://doi.org/10.1536/ihj.18-584

    Article  CAS  PubMed  Google Scholar 

  62. Okamoto T, Hatakeyama S, Hosogoe S, Tanaka Y, Imanishi K, Takashima T, Saitoh F, Suzuki T, Ohyama C (2018) Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis. PLoS One 13(7):e0199160. https://doi.org/10.1371/journal.pone.0199160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Van Laecke S, Van Biesen W, Vanholder R (2012) Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 27(11):4003–4010. https://doi.org/10.1093/ndt/gfs126

    Article  PubMed  Google Scholar 

  64. Xiong J, He T, Wang M, Zhang Y, Wang Y, Huang Y, Feng B, Zhang J, Zhao J (2019) Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis. J Nephrol 32(5):791–802. https://doi.org/10.1007/s40620-019-00601-6

    Article  CAS  PubMed  Google Scholar 

  65. Wu L, Cai K, Luo Q, Wang L, Hong Y (2019) Baseline serum magnesium level and its variability in maintenance hemodialysis patients: associations with mortality. Kidney Blood Press Res 44(2):222–232. https://doi.org/10.1159/000498957

    Article  CAS  PubMed  Google Scholar 

  66. Cervelli MJ, Shaman A, Meade A, Carroll R, McDonald SP (2012) Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Nephrology (Carlton) 17(5):458–465. https://doi.org/10.1111/j.1440-1797.2012.01604.x

    Article  CAS  Google Scholar 

  67. Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP (2016) Proton pump inhibitors accelerate endothelial senescence. Circ Res 118(12):e36–e42. https://doi.org/10.1161/CIRCRESAHA.116.308807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, Virtuoso LP, Egilmez NK, Zhu L (2013) Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol 48(12):1343–1352. https://doi.org/10.1007/s00535-013-0774-5

    Article  CAS  PubMed  Google Scholar 

  69. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP (2013) Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128(8):845–853. https://doi.org/10.1161/CIRCULATIONAHA.113.003602

    Article  CAS  PubMed  Google Scholar 

  70. Liu X, Xu X, Shang R, Chen Y (2018) Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Nitric Oxide 78:113–120. https://doi.org/10.1016/j.niox.2018.06.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Tsai I-J, Lai T-S, Shiao C-C, Huang T-M, Wang C-H, Tsao C-H, Chen L-W, Lin Y-H, Chen L, Wu V-C, Chu T-S, National Taiwan University Hospital Study Group on Acute Renal Failure (NSARF) (2020) Proton-pump inhibitors augment the risk of major adverse cardiovascular events and end-stage renal disease in patients with acute kidney injury after temporary dialysis. Clin Pharmacol Ther 107(6):1434–1445. https://doi.org/10.1002/cpt.1762

    Article  CAS  PubMed  Google Scholar 

  72. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2014) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85(1):174–181. https://doi.org/10.1038/ki.2013.327

    Article  CAS  PubMed  Google Scholar 

  73. Li T, Wilcox CS, Lipkowitz MS, Gordon-Cappitelli J, Dragoi S (2019) Rationale and strategies for preserving residual kidney function in dialysis patients. Am J Nephrol 50(6):411–421. https://doi.org/10.1159/000503805

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Hôpital Privé de L’Ouest Parisien, Ramsay Santé, 14 Avenue Castiglione del Lago, Trappes, France

    Geoffroy Desbuissons

  2. Department of Nephrology, Hôpital Kremlin-Bicêtre, Assistance Publique des Hôpitaux de Paris, Le Kremlin-Bicêtre, France

    Geoffroy Desbuissons

  3. Department of Nephrology, Hôpital Pitié Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France

    Lucile Mercadal

Authors
  1. Geoffroy Desbuissons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucile Mercadal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffroy Desbuissons.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical statement

There was no research involving human or animal participants.

Informed consent

No consent was needed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Desbuissons, G., Mercadal, L. Use of proton pump inhibitors in dialysis patients: a double-edged sword?. J Nephrol 34, 661–672 (2021). https://doi.org/10.1007/s40620-020-00808-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-020-00808-y

Keywords

Search

Navigation